Adam Glassman

Congratulations to the INHALE-1 team for randomizing the 100th participant in the study! More information on the INHALE-1 study can be found at mannkindcorp.com/inhale1/ or clinicaltrials.gov/ct2/show/NCT04…

#Podcast: JAMA Ophthalmology Web Editor Neil Bressler, MD, and authors @DrcrNet and @AdamGlassman1 discuss "Association of Predominantly Peripheral Lesions on Ultrawide Field Imaging and the Risk of Diabetic Retinopathy Worsening Over Time." ja.ma/3A2hmU5

Some insurance companies mandate a form of step therapy, which involves a trial of an inexpensive drug, bevacizumab, to treat diabetic macular edema. This trial compared two treatments: step therapy and a more expensive drug. #ASRS2022 nej.md/3P9FA4X

New editorial by David C. Musch, Ph.D, M.P.H., and Emily Chew, M.D.: "Evidence for Step Therapy of Diabetic Macular Edema" #ASRS2022 nej.md/3PqogbU

#NEIfunded clinical trial led by @DrcrNet found that in diabetic macular edema, starting with a cheaper drug (Avastin) and switching to a more expensive drug (Eylea) as needed leads to good vision outcomes. @NIDDKgov Read the NEI News report: bit.ly/3O7GtK0

In this study, aflibercept injections reduced the development of vision-threating complications; however, through 2 years, preventive treatment did not confer visual acuity benefit compared with observation plus aflibercept if complications developed ja.ma/2V7yeYv

While intravitreal injection of aflibercept may be a safe alternative for initial management of vitreous hemorrhage from proliferative diabetic retinopathy (PDR), vitrectomy with panretinal photocoagulation remains the standard of care for PDR. ja.ma/34gXqxv

On Capitol Hill today—A Congressional luncheon spotlighting @NatEyeInstitute’s Diabetic Retinopathy Clinical Research Network @DrcrNet and their ongoing research on #DiabeticEyeDisease. Thank you, Dr. Daniel Martin @ClevelandClinic & Dr. Jennifer Sun @JoslinDiabetes!

opmed.doximity.com/articles/arvo-… @ARVOinfo @JAMAOphth @DrcrNet

Watchful waiting okay for diabetic macular edema. Clinical trial results from the #NEI-funded #DRCR Network about #DME treatment announced at #ARVO2019 and published in @JAMA_current. go.usa.gov/xmXpn

Watchful waiting reasonable for patients with diabetic macular edema and good vision nih.gov/news-events/ne…

Despite the availability of therapies for #diabetic #retinopathy, it is imperative that clinicians educate patients about the importance of medical therapies. Just released for #ARVO2019 ja.ma/2GGlQUG

Congratulations DRCR Retina Network. Protocol V primary results are in. Effect of Aflibercept, Laser Photocoagulation, or Observation on Vision Loss in Diabetic Macular Edema ja.ma/2XU79El #JAMA, #ARVO

Younger participant age, lower #hbA1c and absence of Prior PRP were associated with better 2-year vision outcomes in DRCRnet Protocol T ja.ma/2FPtn5C @DrcrNet

Available Now. Protocol T: Early Response to Anti-VEGF and 2-Year Outcomes in DME  | authors.elsevier.com/c/1XgaOgnY~zw8…

ja.ma/2JPJQEt Protocol S 5-year outcomes for PDR, either PRP or #ranibizumab yield good mean VA; severe #visionloss rare. Learn more from @AdamGlassman1 ja.ma/2JSQNo3 #ASRS2018

With any of the 3 anti-VEGF agents, even if #diabetic #macular #edema chronically persists, eyes typically achieve vision gain, rarely loss #Diabetes ja.ma/2FzDE1z

Adding Dexamethasone to Ranibizumab for Patients With Persistent Diabetic Macular Edema ja.ma/2zvugwn

#Dexamethasone+#ranibizumab for persistent #DME, does not improve VA more but does reduce DME more vs only ranibizumab ja.ma/2mfM85L

#Dexamethasone + #ranibizumab for persistent #diabetic #macularedema, does not improve VA more but does reduce diabetic macular edema more vs ranibizumab alone ja.ma/2By1olq